»«a«*r.awm
. a xm'z am -/* «w'm. <
.
* ---^^ 5W-W, M,V!
*
w vwmavi' » 4wta*>« *
: *&WDJPS*¥Ck
Approved For Release 2 ‘SECRET m 96-00788R001 5001 1 0001 -4
1,
(5/N0E0RN-CL)
GENERAL
1.1
The objective
of this effort
is to investigate
a particular aspect
of the psychoenergetic phenomena known as remote viewing that has potential
military intelligence application.
Coordinate Remote Viewing
(CRV)' is
a
staged technique which utilizes coordinates
to facilitate acquisition of
a
remote viewing target.
1.2
Major goals are the determination
if CRV technology can be successfully
transferred to INSC0M personnel with
a corresponding increase
in
the reliability
of
a remote viewer.
2.
(S/N0F0RN-CL)
SPECIFIC TASK
2.1
Train army personnel
in CRV Stages
III and
IV.
2.1.1
Initiate training at the highest skill level
(CRV Stage)
of the
trainee.
2.1,2
Training for each CRV stage will normally
be divided into three
two week working
sessions.
The Session
dates will be mutually agreed to
by
SRI
and INSC0M.
2.1.3
After successful completion of CRV Stage
III,
schedule the trainee
to begin
CRV Stage
IV.
2.2
Determine the potential
of the trainee
for further training.
3,
(U)
SECURITY
Military security requirements
in the performance
of this contract shall be
maintained
in accordance with DD Form
254 attached hereto.
The highest
classification
involved
in the performance of this contract
is SECRET-
NO FOREIGN DISSEMINATION.
4.
(S/N0F0RN-CL)
DELIVERABLES:
The contractor will provide the following.
4.1
State-of-The-Art CRV training,
4.2
Progress report
(2 copies):
Written evaluation
of trainee progress
at the completion
of each two week working session.
4.3
Final
Report:
4.3.1
A final
report
in
3 copies will be furnished within 30 days
after completion
of the
CRV
stage.
4.3.2
Report will
include
a summary
of the training presented;
an
evaluation
of the trainee's ability to understand the training;
and
a summary
of the trainee's accomplishments during the training period.
4.3.3
Report should also include an evaluation
of the trainee's
future remote viewing capabilities.,
and
a recommendation concerning further
training.
vAftPfi3W©drF0JSRietease 2001 /£4^^©Jj£RDP96-00788R001 5001 1 0001 -4
INTELLIGENCE SOURCES AND
„
JllllML I ^
NOT RELEASABLE 10 E0EEIGH HATIONALS
METHODS INV.Olr.YEQ
VbWi'fc
NUA
DP96-00788R001 5001 1 0001 -4
5,
.
(S/N0F0RN—CL )
POST TRAINING ACCESS:
After the completion of each CRV
training stage personnel
involved in the
training program will have
reasonable access to INSCOM personnel trained to assist in further evaluation of
CRV,
6,
(U)
SPECIAL REUQIREMENTS
6.1
Use
of human subjects
()
The following definitions are used:
(1)
At
risk means that
the human subject may be exposed to the
possibility
of harm
- physical,
biological,
psychological,
sociological,
or other
~
as
a consequence of an
act
or omission that goes beyond the application
of those established and accepted methods or procedures which are in his
best
interests,
or that increases ordinary risks of daily
life,
including the
recognized risks inherent
in his chosen occupation
or field of service.
(2)
Human subject means any human being who,
knowingly
or unknowingly,
is subjected to an act or omission,
whether at
risk
or not,
the object of
which is to contribute
to knowledge to be gained as a part of work to be
performed under the scope
of this contract.
. (b)
The contractor,
before undertaking to perform any study involving
human subjects,
whether at risk
or not,
shall insure that the following minimum
conditions are complied with:
(1)
The proposed study has been reviewed and approved by
a committee
meeting the
requirements set forth
in Chapter 46 of Title 45 of the Code
of
federal Regulations.
P
(2)
The number of human subjects used will be kept
to the minumum number
that will reasonably achieve the required results.
(3)
The study must
be such as
to contribute significantly to scientific
knowledge and have reasonable prospects of yielding important results essential
to
an
Army research program.
(4)
The study will
be conducted only
by persons possessing the
requisite scientific qualifications.
The highest degree
of skill and care
will be required during all stages of study
of persons who conduct or assist
in the study.
(5)
The human subject will be informed that
at any time during the
course of his participation
he has the
right
to revoke his consent and
withdraw from participation without prejudice to himself.
()
Participation by subjects will
be immediately terminated if
it
subsequently appears that the risk to the subjects is significantly greater
than anticipated
at the time review and approval was granted.
»e 2001/0
METHODS INVOLVED
96-00788R001 5001 1 0001 -4
KOI RELEASABLE 10 FOREIGN NATIONALS
Approved For Release 2001/04
88R001 5001 10001 -4
(7)
There shall bo no greater intrusion into the privacy
of the
human subject than
is absolutely necessary
for the conduct
of the study
involved.
Except
for the submission
of reports and other data required by
this contract,
any information obtained about human subjects as
a result
of
participation
shall
be held as confidential
as the law allows.
(8)
The study will be conducted so as to avoid all unnecessary
physical or mental suffering
or injury.
(9)
No study will be conducted
if there
is any inherent reason to
believe that death
or disabling
injury
is likely to occur.
Sufficient
animal
or laboratory experiments,
or other evaluations,
must have been completed
to give assurance of acceptable risks prior to the use of human subjects.
(10)
The degree
of risk to be taken will never exceed that which
is
justified by the benefit
to the subject and/or the humanitarian importance
of the knowledge to be gained.
(11)
A physician will be responsible
for the medical care of
subjects.
Even
if not the project leader,
the physician will have authority
to terminate the
study
at
any time that he believes death,
injury or harm
is likely
to result.
(12)
Proper preparations will be made,
and adequate facilities provided
to protect
the subject against all foreseeable possibilities
if injury,
disability
or death.
This includes but
is not limited to hospitalization
and medical treatment
as may be
required.
In addition,
all apparatus and
instruments necessary to deal with likely emergency situations will be
available
.
(13)
Human subjects will have no physical or mental conditions, which
will make participation more hazardous for them than
it would be for normal
healthy
persons,
unless such condition
is
a necessary prerequisite for
the
particular study involved.
In
any
such case,
the
use
of human subjects with
such pre-existing conditions must have been specifically described and
justified
in the scope of the work to be performed under this contract
.
(14)
The scientifically qualified person conducting the study,
and each member
of his research team,
will be prepared to terminate the
subject's participation
at
any stage
if
he has reason
to believe,
in the
exercise
of the good faith,
superior skill,
and careful judgement required
of
him,
that continuation
is likely
to result
in
injury,
disability,
or death
to the human subject.
(c)
The contractor,
before permitting any person
to participate
as
a human
subject,
whether
at risk or not, shall insure that
the following
minimum conditions are
complied
with:
(1)
Legally effective informed consent will be obtained by adequate
and appropriate methods
in accordance with the provisions
of this clause.
2001/04/02
: CIA-RDP96-00788R001 5001 10001 -4
JNTF-LUGPNCE SOoROt-S-JWH
...
Tinrfl T)T.T7 rpn •jrrVRTSTflN
METHODS IWVQVVER
u f oorwu
i uuu
i
i uuv
i -‘t
NOT RELEASABLE TO FOREIGN NATIONALS
Approved For Release 2001
788R001 5001 10001 -4
(2)
All consent must be voluntary.
It must be the knowing consent
of the individual
or his legally authorized representative,
so situated as
to be able
to exercise
free power
of choice without there having been any
use of force,
fraud,
deceit,
duress,
constraint,
coercion,
or lawful or
improper inducement.
The elements of information necessary to such consent
includes
(i)
A' fair explanation
of the procedures to be followed,
and their
purposes,
including identification
of any procedures which are experimental.
(ii)
A description of any attendant discomforts or risks reasonably
to be anticipated.
(iii)
A description of any benefits reasonably to be anticipated.
(iv)
A disclosure of any appropriate alternative procedures that
might be advantagious to the subject.
(v)
An offer to answer any questions concerning the procedure.
(vi)
An instruction that the subject
is free to revoke his consent
and to discontinue participation at any time without prejudice to himself.
(d)
Exculpatory language through which the subject
is made to
waive,
or appear to waive,
any
of his legal
rights,
including any release
from liability for negligence,
is prohibited.
(e)
Prior consent
by
a subject
or his legally authorized
representative shall be obtained
in all
cases.
Such consent shall
be
in
writing whenever it
is reasonably possible
to
do so.
The consent form
may be read to the subject
or his legally authorized representative,
but
in
any event he or his legally authorized representative must be given adequate
opportunity
to
read it and to ask questions they might have.
This consent
form should then be signed by the subject or his legally authorized
representative and by
a witness not directly involved
in the
study.
Oral
consent may be used only when
it has been specifically described and
justified
in the scope
of
the work to be performed under this contract
or
approved
in writing by the contracting officer.
When
so authorized and used,
oral consent
is subject to all
the same standards
as apply to written consent,
except that the signature of the subject or his legally authorized
representative
is not
required.
(f)
Prior to conduct of the study,
the contractor shall submit for
approval
to the contracting officer’s representative
a detailed description
of the means by which informed consent will be obtained,
to
include any forms
to be
used.
Upon completion of the study,
the contractor will submit
to the contracting officer's representative
a detailed
report demonstrating
compliance with paragraph
(c),
to include copies of the written consent
if
such was obtained.
(g)
The contractor shall not undertake
to conduct either the clinical
pharmacology
or clinical trails of
an
investigational
drug unless this
contract
contains the clause entitled "Clinical Study
of
Investigational Drugs."
warAppicovi^d;)F^fs5pfele>ase 2004/04/02 p©IA*REDR964WD788R00 16001 10004 -4
INTELLIGENCE SOURCES ANQ
METHODS INVOWm
Prmn "
K0T^SASABLE 10 E0KEIGN MII0KAI,S
Approved For Release 2001/0
788R001 5001 10001 -4
6,2
DoD Direcive
5240. 1-R governing experimentation
on human subjects
will be followed by the contractor.
Informed consent
of all subjects will
be obtained
in writing
in accordance with the guidelines issued by the
Department
of Health,
Education and Welfare.
All persons participating
as human
subjects,
as defined
in paragraph 6.1 above shall be
known to
possess the abilities and qualities which will be observed
and analyzed
during the
conduct
of this contract.
5001 1 0001 -4
METHQDC. ii'ivuivi.ft
]jj0T KETjEASABIE TO EOBEIGN EATlONAliS
Approved For Release 2001/04tf^^P^^&^A788R001 5001 1 0001 -4
JUSTIFICATION FOR SOLE SOURCE PROCUREMENT
1.
(S)
SRI
International
is uniquely qualified for this
3ole source
procurement
by virtue of
a combination
of experience and performance.
2.
(S/NQF0RN)_
SRI
International
is
a recognized leader in the field of
psychoenergetics and has performed similar work for other
U.S.
Government
agencies over the past feu/ years.
Previous
u/ork,
under DIA contracts
MDA-9Q8--81-C--0292 and MDA-9G8-92-C-Q034 has formed
a highly meaningful
data
base which will greatly enhance
the value and effectiveness of this new
contractual effort.
3.
(S)
The
effort involved for a new contractor to research the
.same level
of capability and expertise that
SRI
currently possesses for this area would
be too time consuming and uneconomical to acquire and develop.
To acquaint
a new contractor
in this area of expertise,
if he could be found,
would
require several years simply
to achieve the present level
of expertise and
competence possessed by
SRI
International,
SENSITIVE
METHODS LMV-QUVEQ
»a—